Uniqure NV

QURE remains in a Stage 2 uptrend with price supported by rising EMAs. The recent shallow pullback into the 9/20 EMA zone has held support, favoring continuation. Medium-term structure is bullish above the rising 50 DMA with clear higher highs and lows, while short-term timing conditions align for a Buy Now entry on the EMA pullback despite overbought context.

• ↑AMT-130 BLA filed under accelerated pathway after 75% disease-slowing in 3-year trial.
• ↑$810M cash balance expected to fund operations through 2030, reducing dilution risk.
• ↓FDA indicates Phase 1-2 data may lack sufficient primary evidence, delaying BLA approval.